Frequently Asked Questions
What is Algernon NeuroScience?
Algernon NeuroScience is a wholly owned private equity subsidiary of Algernon Pharmaceuticals and has been created to advance the Company’s DMT stroke and traumatic brain injury research program.
When was Algernon NeuroScience established?
AGN Neuro was incorporated on December 9, 2022
What was the date that the Form 1-A offering statement filed by Algernon NeuroScience was qualified by the SEC?
The Form 1-A was qualified by the SEC on March 8, 2023
Where is Algernon NeuroScience located?
Suite 400-601 West Broadway,
Vancouver, British Columbia
V5Z 4C2
When is Algernon NeuroScience’s fiscal year end?
August 31
Who is Algernon NeuroScience’s independent auditor?
Smythe LLP
Suki Gill
475 Howe Street
Suite 1700
Vancouver, BC V6C 2B3
Canada
T: 604-687-1231
sgill@smythe.com
Who is Algernon NeuroScience’s outside legal counsel?
Sheppard, Mullin, Ritcher & Hampton LLP
30 Rockefeller Plaza
New York, NY 10112
T: +1.212.653.8700
McMillan LLP
Desmond Balakrishnan
1055 West Georgia Street
Suite 1500
Vancouver, BC V6E 4N7
Canada
T: 604-689-9111